)
Exact Sciences (EXAS) investor relations material
Exact Sciences AGM 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Opening remarks and agenda
Meeting called to order by the Chairman, with board members and key officers present.
Inspector of Election confirmed and agenda, rules of conduct, and Q&A procedures outlined.
Shareholder proposals
Three proposals presented: approval of merger agreement, advisory vote on executive compensation related to the merger, and potential adjournment to solicit more proxies.
Q&A with stakeholders
Stockholders could submit questions online, limited to one per person, with follow-up promised for unanswered questions.
Updates provided on regulatory approvals (expected completion before end of Q2 2026) and reference to SEC filings for merger-related litigation.
- Multi-cancer early detection could cut late-stage cancer by 40% and mortality by 18%.EXAS
7th Annual Healthcare Symposium - International expansion accelerates with new products, offices, and integration with Abbott.EXAS
Proxy Filing - Record revenue, improved cash flow, and major merger plans mark a transformative year.EXAS
Q4 2025 - Merger with Abbott at $105 per share prompts supplemental disclosures and litigation response.EXAS
Proxy Filing - Q2 revenue up 12% to $699M; record test volumes and raised EBITDA guidance.EXAS
Q2 2024 - Cologuard Plus and a robust pipeline position the company for sustained growth and market leadership.EXAS
Jefferies Global Healthcare Conference - All proposals passed, with director elections, auditor ratification, and no shareholder questions.EXAS
AGM 2024 - Cologuard Plus, automation, and global expansion fuel strong growth and margin gains.EXAS
Goldman Sachs 45th Annual Global Healthcare Conference - Growth driven by innovation, digital integration, and organizational agility, with guidance reaffirmed.EXAS
The 44th Annual William Blair Growth Stock Conference
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)